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Abstract
Introduction Current and recent users of hormone replacement
therapy (HRT) have an increased risk of being recalled to
assessment at mammography without breast cancer being
diagnosed ('false positive recall'), but there is limited information
on the effects of different patterns of HRT use on this. The aim
of this study is to investigate in detail the relationship between
patterns of use of HRT and false positive recall.
Methods A total of 87,967 postmenopausal women aged 50 to
64 years attending routine breast cancer screening at 10 UK
National Health Service Breast Screening Units from 1996 to
1998 joined the Million Women Study by completing a
questionnaire before screening and were followed for their
screening outcome.
Results Overall, 399 (0.5%) participants were diagnosed with
breast cancer and 2,629 (3.0%) had false positive recall.
Compared to never users of HRT, the adjusted relative risk
(95% CI) of false positive recall was: 1.62 (1.43–1.83), 1.80
(1.62–2.01) and 0.76 (0.52–1.10) in current users of
oestrogen-only HRT, oestrogen-progestagen HRT and tibolone,
respectively (p (heterogeneity) < 0.0001); 1.65 (1.43–1.91),
1.49 (1.22–1.81) and 2.11 (1.45–3.07) for current HRT used
orally, transdermally or via an implant, respectively (p
(heterogeneity) = 0.2); and 1.84 (1.67–2.04) and 1.75 (1.49–
2.06) for sequential and continuous oestrogen-progestagen
HRT, respectively (p (heterogeneity) = 0.6). The relative risk of
false positive recall among current users appeared to increase
with increasing time since menopause, but did not vary
significantly according to any other factors examined, including
duration of use, hormonal constituents, dose, whether single- or
two-view screening was used, or the woman's personal
characteristics.
Conclusion Current use of oestrogen-only and oestrogen-
progestagen HRT, but not tibolone, increases the risk of false
positive recall at screening.
CI = confidence interval; HRT = hormone replacement therapy; NHSBSP = National Health Service Breast Screening Programme; RR = relative risk.Breast Cancer Research    Vol 8 No 1    Banks et al.
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Introduction
Around one-third of women attending the UK National Health
Service Breast Screening Programme (NHSBSP) from 1996
to 2000 were using hormone replacement therapy (HRT) at
the time and about 16% were former users [1]. Women under-
going mammography are at a higher risk of being recalled to
assessment with no subsequent diagnosis of breast cancer
('false positive recall') if they are current users of HRT, com-
pared to women who are not currently using HRT [2,3].
Among past users of HRT, the elevated risk of false positive
recall diminishes significantly with increasing time since last
use of HRT but still appears to be elevated among women
ceasing use within the last five years [3]. Details regarding the
effect of different patterns of use of HRT on the risk of false
positive recall, including the effect of duration of use of HRT
and use of different HRT preparations, are lacking, and it is not
clear whether the effects of current and past use of HRT vary
between women with different characteristics and between
studies.
This study investigates in detail the effects of different patterns
of use of HRT on the risk of false positive recall, as well as the
consistency of HRT effects. It also presents a meta-analysis of
results from studies examining the effect of current and past
use of HRT on false positive recall.
Methods
At the time of the study, all 50 to 64 year old women in the UK
who were registered with a general practitioner were invited to
attend the NHSBSP approximately once every three years for
routine mammographic screening. The NHSBSP is aimed at
screening asymptomatic women, whereas women with symp-
toms are encouraged to consult their general practitioner.
Women recruited into the Million Women Study (described in
detail elsewhere [4]) who attended screening at ten selected
breast screening units (Avon, Gloucestershire, Hereford and
Worcester, Manchester, North Lancashire, Oxfordshire, Port-
smouth, Warwickshire Solihull and Coventry, West of London
and West Sussex) from June 1996 to the end of March 1998,
were followed in detail for their outcome at screening. The
women received a study questionnaire accompanying their
invitation and were asked to return the completed form when
they attended for screening. The questionnaire requested
information regarding lifestyle and socio-demographic factors,
reproductive factors, past health and use of HRT, and asked
for signed consent for follow-up. The recruitment question-
naire can be viewed at the study website [5]. At the time of
recruitment, nine of the ten screening centres used two-view
mammography at the first screening round and single-view
mammography at subsequent rounds; one centre used two-
view mammography for all screens.
Definitions
The variables for these analyses, including use of HRT, were
defined according to what was reported on the recruitment
questionnaire, that is, at baseline. Women were asked which
specific proprietary preparation of HRT they had used most
recently, and for these analyses the preparations are grouped
according to the hormonal constituents of each preparation
listed in the British National Formulary [6]. Women whose peri-
ods had ceased either naturally or as the result of a bilateral
oophorectomy are defined as postmenopausal. Women aged
55 and over who had had a hysterectomy without oophorec-
tomy were also defined as postmenopausal, as were women
aged 55 and over who began use of HRT before their natural
menopause [7].
An outcome of screen-detected breast cancer was defined as
histologically confirmed screen-detected breast cancer (inva-
sive cancer or carcinoma in situ), according to the pathology
information recorded by the screening centre. 'False positive
recall' was defined, according to screening centre records, as
being recalled to assessment following initial screening mam-
mography, without a subsequent diagnosis of screen-
detected breast cancer during that screening episode.
Women with technically inadequate films that needed to be
repeated were classified according to the results of their
repeat mammogram.
Analysis
These analyses include 87,967 postmenopausal women aged
50 to 64 years who did not report a past history of cancer
(except non-melanoma skin cancer) at recruitment. (This
includes a small number (n = 2,527, 2.9%) who were aged 49
or 65 years when screened, but were close to their 50th or
65th birthday, since women are invited to screening according
to their year of birth, rather than their exact age.)
Relative risks (RR) are estimated as odds ratios and 95% con-
fidence intervals (CI) calculated by conditional logistic regres-
sion, stratifying by screening centre, age at screening (50 to
52, 53 to 55, 56 to 58, 59 to 61, 62 to 64), time since meno-
pause (<5 years, 5 to 9 years, ≥10 years), reported previous
breast screening (no, yes), body mass index (<25 kg/m2, ≥25
kg/m2) and history of previous breast surgery for a condition
other than breast cancer (no, yes). All adjustment factors
include an 'unknown' category. Adjustment for other potential
confounding factors, such as deprivation index, educational
attainment, family history of breast cancer, age at first birth and
parity, had no material effect on the findings and are, therefore,
not included in the analyses. All tests for trend by duration and
time since last use of HRT were calculated using the appropri-
ate median duration or time since last use in each category.
Where results are presented graphically, relative risks are
shown as black squares with areas inversely proportional to
the variance of the log relative risk, indicating the amount of
statistical information available for that particular estimate. TheAvailable online http://breast-cancer-research.com/content/8/1/R8
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Table 1
Breast cancer screening outcome in postmenopausal women for users of HRT compared to never users
Total women 
screened
(n = 87967a)
Women recalled to assessment Adjusted RR 
(95% CI) of false 
positive recallb
Heterogeneity/trend,
p-value
No breast cancer (false 
positive recall)
Screen-detected breast 
cancer
%n%n
Total 87,967 3.0 2,629 0.5 399
Never used HRTc 44,620 2.4 1,057 0.4 193 1.00 χ2
1 (heterogeneity)
= 90.1,
Ever used HRT 43,332 3.6 1,572 0.5 206 1.47 (1.36–1.60) P < 0.001
Past user of HRT 13,829 2.8 382 0.3 48 1.21 (1.06–1.38)
Time since last use 
(median)
χ2
1 (trend) = 14.0,
p < 0.001
Current user (0 years) 28,788 4.0 1,157 0.5 154 1.64 (1.50–1.80)
<1 year since last use 
(0.5 years)
1,764 3.6 63 0.3 6 1.42 (1.08–1.86)
1–4 years since last 
use (2 years)
5,931 3.0 176 0.4 21 1.23 (1.04–1.46)
≥5 years since last use 
(7 years)
3,813 2.4 92 0.3 13 1.07 (0.85–1.34)
Duration of use among 
current users of HRT 
(median)
χ2
1 (trend) = 2.1,
p = 0.2
<1 year (0.5 years) 1,935 3.9 75 0.3 5 1.41 (1.10–1.81)
1–4 years (3 years) 9,790 4.2 410 0.6 54 1.58 (1.40–1.79)
5–9 years (6 years) 11,280 3.9 441 0.6 71 1.74 (1.53–1.97)
≥10 years (11 years) 4,963 3.9 193 0.4 21 1.74 (1.46–2.06)
Duration of use among 
past users of HRT 
(median)
χ2
1 (trend) = 8.4,
p = 0.004
<1 year (0.5 years) 4,014 2.4 95 0.3 13 0.95 (0.77–1.18)
1–4 years (3 years) 5,152 2.8 143 0.3 17 1.29 (1.07–1.56)
≥5 years (8 years) 3,061 3.4 104 0.5 14 1.54 (1.23–1.93)
aNumbers do not always add up to total due to missing values. bStratified by screening centre, age, time since menopause, previous screening, 
body mass index and previous breast operation. cReference group. CI, confidence interval; HRT, hormone replacement therapy; RR, relative risk.
corresponding confidence intervals are shown as horizontal
lines.
Meta-analysis
Articles presenting original epidemiological data on the effect
of current and past use of HRT on the risk of false positive
recall were located through searches of PubMed, the Science
Citation Index and through searching reference lists of located
references. Information on the relative risk of false positive
recall in current and past users of HRT compared to never
users was extracted and presented graphically. The summary
relative risk was calculated as the exponent of the average ofAvailable online http://breast-cancer-research.com/content/8/1/R8
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the log relative risks for the relevant studies, weighted accord-
ing to the inverse of the variance of the individual log relative
risks.
Results
Among 87,967 participating postmenopausal women, 3,043
(3.5%) were recalled to assessment and 3,028 attended this
assessment; 15 women (0.02%) were lost to follow-up due to
having defaulted attendance at assessment and/or having
chosen to be investigated outside the National Health Service.
Overall, 399 (0.5%) women were diagnosed with screen-
detected breast cancer, leaving 2,629 (3.0%) women with
false positive recall.
Use of HRT and screening outcome
Table 1 shows the proportion of women experiencing false
positive recall according to use of HRT, along with the associ-
ated relative risk estimates and their confidence intervals.
Stratifying by screening centre, age, time since menopause,
previous breast screening, body mass index and previous
breast surgery, women who had ever used HRT had a signifi-
cantly higher risk of false positive recall, compared to women
who had never used HRT (RR 1.47, 95% CI 1.36–1.60), and
this relative risk was particularly elevated among current users
(RR 1.64, 95% CI 1.50–1.80) (Table 1). Women who had
used HRT in the past were also at a significantly increased risk
of false positive recall compared to never users (RR 1.21,
95% CI 1.06–1.38) and this relative risk differed significantly
from that in current versus never users of HRT (χ2
1(heteroge-
neity) = 13.7, p < 0.001). There was a significant trend in
recall according to time since stopping use of HRT (χ2
1(trend)
= 14.0, p < 0.001), suggesting the wearing off of the effect of
HRT over time in past users [3].
Among current users of HRT, the relative risk was significantly
elevated in all duration groups, including those women who
had been using HRT for less than one year, and there was no
significant trend in the relative risk according to duration of use
(Table 1). In contrast, there was a significant trend of increas-
ing risk of false positive recall with increasing duration of use
in past users (Table 1). Recent users of HRT are more likely to
have used it for long durations, and there were insufficient data
to separate out reliably the effects of duration of use and time
since last use among past users of HRT.
The relative risk of false positive recall differed significantly
according to whether a woman was currently using oestrogen-
only, oestrogen-progestagen or other types of HRT: RR (95%
CI) 1.62 (1.43–1.83), 1.80 (1.62–2.01) and 0.95 (0.73–
1.23), respectively (χ2
2(heterogeneity) = 22.2, p < 0.0001)
(Fig. 1). This was mainly because the relative risk (95% CI) of
false positive recall among current users of tibolone was 0.76
(0.52–1.10) compared to women who had never used HRT,
and the difference in the relative risk of false positive recall
between women currently using oestrogen-only, oestrogen-
progestagen and tibolone was highly significant (χ2
2(hetero-
geneity) = 21.0, p < 0.0001). There was no significant differ-
ence in the relative risk of false positive recall between women
using oestrogen-only and oestrogen-progestagen HRT
(χ2
1(heterogeneity) = 2.3, p = 0.1) [3].
Among women currently using oestrogen-only or oestrogen-
progestagen HRT, there was no significant difference
observed according to the type of oestrogen (for conjugated
equine oestrogen versus oestradiol, χ2
1(heterogeneity) = 0.5,
p = 0.5) or type of progestogen (for medroxyprogesterone
acetate versus norethisterone versus norgesterel/levonorges-
terel, χ2
2(heterogeneity) = 4.3, p = 0.1) in use, according to
the dose of oestrogens currently being used (for conjugated
equine oestrogen ≤0.625 mg versus >0.625 mg, χ2
1(hetero-
geneity) = 3.0, p = 0.08; for oestradiol ≤1 mg versus >1 mg,
χ2
1(heterogeneity) = 0.5, p = 0.5; for oestradiol ≤50 µg versus
>50 µg, χ2
1(heterogeneity) = 3.4, p = 0.07) or according to
whether the oestrogen was taken orally, via a patch or an
implant (χ2
2(heterogeneity) = 2.8, p = 0.2) (Fig. 1). There was
no significant difference in the relative risk of false positive
recall between those using sequential and continuous oestro-
gen-progestagen HRT (χ2
1(heterogeneity) = 0.3, p = 0.6).
The consistency of the effect of HRT
To examine how consistent the effects of current and past use
of HRT are across other possibly relevant factors, the adjusted
relative risks of false positive recall and 95% confidence inter-
vals in current and past users of HRT compared to never users
are presented (Fig. 2). Significant heterogeneity was observed
in the effect of current use of HRT (global χ2
20(heterogeneity)
= 38.2, p = 0.01), which was chiefly the result of variation
according to the closely related factors of age within screen-
ing round and time since menopause. Although this heteroge-
neity appeared to be greater for time since menopause than
for age, there were insufficient data to investigate their dual
effects. There was no significant heterogeneity in the effect of
HRT according to whether or not women had had a previous
screen, after accounting for age. No significant heterogeneity
was present for current use of HRT for any other factors exam-
ined, nor was significant heterogeneity found for the effect of
past use of HRT (global χ2
20(heterogeneity for past use) =
18.1, p = 0.6). These included comparisons between the dif-
ferent screening centres (Fig. 2), in that there was no signifi-
cant difference between the nine centres using single-view
mammography among previously screened women (centres A
to E and G to J) and the centre using two-view mammography
among previously screened women (centre F) (χ2
1(heteroge-
neity for current use) = 1.1, p = 0.3; χ2
1(heterogeneity for past
use) = 0.2, p = 0.7).
Figure 3 summarises the results of this study, along with pre-
vious studies that have compared the risk of false positive
recall among current and past users of HRT separately with
that for never users [8-10]. The overall results show a signifi-Available online http://breast-cancer-research.com/content/8/1/R8
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cantly elevated risk of false positive recall among current users
of HRT compared to never users, and a lesser, but still signifi-
cant, increase in risk among former users. There is significant
heterogeneity in the results for current use of HRT but not for
past use.
Discussion
Women who have ever used HRT are at an increased risk of
false positive recall compared to never users. The relative risk
is greatest in current users and, among past users, declines
significantly with increasing time since ceasing use [3]. The
Figure 1
Relative risk (RR) of false positive recall in current versus never-users of hormone replacement therapy (HRT), by preparation currently used Relative risk (RR) of false positive recall in current versus never-users of hormone replacement therapy (HRT), by preparation currently used. *Strati-
fied by screening centre, age, previous screening, body mass index and previous breast operation. Relative risks are shown as black squares with 
areas inversely proportional to the variance of the log relative risk, indicating the amount of statistical information available for that particular estimate. 
The corresponding confidence intervals (CI) are shown as horizontal lines. An arrow is used where the upper confidence limit exceeds the scale of 
the figure. The diamond represents the overall relative risk and 95% CI of false positive recall in current versus never-users of HRT.Breast Cancer Research    Vol 8 No 1    Banks et al.
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relative risk of false positive recall was elevated to a similar
extent in users of oestrogen-only and oestrogen-progestagen
HRT. The risk of false positive recall in women using tibolone
did not differ significantly from that in never users.
The study described here is large and population-based,
meaning that major effects of HRT on false positive recall can
be quantified and generalised to the screened population in
the UK. Detailed prospective data were gathered on the use of
HRT immediately prior to screening, including information on
current and past use, along with the type (that is, the hormonal
constituents) and dose of the preparation currently being
used. These data have shown excellent agreement with gen-
eral practice prescription records [11]. It should be noted,
however, that the study had limited power to test for differ-
ences in the effect of HRT according to the number of mam-
mographic views in use by different screening centres.
Previous results from the Million Women Study have shown
that false positive recall is increased in women who are pre-
menopausal, those without a previous NHSBSP mammogram,
those reporting previous breast surgery, those who are nullipa-
rous and those with a lower body mass index [7]. The availa-
bility of prospectively gathered information on a range of
demographic, reproductive and lifestyle factors, including
Figure 2
Relative risk (RR) of false positive recall in relation to hormone replacement therapy (HRT) use, in various subgroups of women Relative risk (RR) of false positive recall in relation to hormone replacement therapy (HRT) use, in various subgroups of women. *Relative to never-
users, stratified by screening centre, age at screening, previous screening, body mass index, previous breast operation and time since menopause 
(where appropriate). Relative risks are shown as black squares with areas inversely proportional to the variance of the log relative risk, indicating the 
amount of statistical information available for that particular estimate. The corresponding confidence intervals (CI) are shown as horizontal lines. An 
arrow is used where the upper confidence limit exceeds the scale of the figure.Available online http://breast-cancer-research.com/content/8/1/R8
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carefully ascertained and classified data on menopause,
allowed consideration of these and other important potential
confounding factors [1,7].
Current use of HRT was associated with increased false pos-
itive recall soon after use commenced. This is consistent with
three previous comparable publications, which all show signif-
icant increases in the risk of false positive recall with current
use of HRT (Fig. 3). There is, however, significant heterogene-
ity between studies in the magnitude of this effect between
studies. The two studies with the lowest relative risks included
premenopausal and perimenopausal women [9,10] and not
being able to account for this confounding factor [7] may have
diluted the findings. Differences in time since menopause
among study participants may also have differed between
studies. Furthermore, there are large variations in recall rates
in different screening programmes, reflecting differences in
diagnostic thresholds and other factors, which may also
impact on the size of the effect of HRT. The Women's Health
Initiative randomised controlled trial found significantly ele-
vated risks of false positive recall among women randomised
to oestrogen-progestagen HRT compared to placebo from the
first year following randomisation onwards, further supporting
the findings of increased false positive recall soon after com-
mencing use of HRT [12].
The effect of current use of HRT was not significantly related
to duration of use and, among women using oestrogen alone
or combined oestrogen/progestogen, did not differ signifi-
cantly according to the type of oestrogen and/or progestogen
in current use, according to the dose of oestrogen currently in
use or according to the mode of delivery of the oestrogen. Two
previous smaller studies with data on false positive recall and
use of oestrogen-only and oestrogen-progestagen HRT also
report no substantive differences in the risk between users of
these types of HRT [8,9]; one of these studies suggested pos-
sible differences in false positive recall between other HRT
regimens, based on small numbers of events, and called for
more extensive research in this area [9]. Findings regarding
false positive recall in users of tibolone have not, to our knowl-
edge, been reported before.
Overall, former users of HRT had a significantly lower risk of
false positive recall than current users but a significantly higher
Figure 3
Published results on the relative risk (RR) of false positive recall in relation to use of hormone replacement therapy (HRT) Published results on the relative risk (RR) of false positive recall in relation to use of hormone replacement therapy (HRT). Test for heterogeneity for 
current use of HRT versus never, χ2
3 = 13.9, p = 0.003. Test for heterogeneity for past use of HRT versus never χ2
3 = 6.8, p = 0.08. Relative risks 
are shown as black squares with areas inversely proportional to the variance of the log relative risk, indicating the amount of statistical information 
available for that particular estimate. The corresponding confidence intervals (CI) are shown as horizontal lines. An arrow is used where the upper 
confidence limit exceeds the scale of the figure. The diamonds represent the summary relative risks and 95% CIs of false positive recall in current 
and past versus never-uses of HRT.Breast Cancer Research    Vol 8 No 1    Banks et al.
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risk than never-users. Although results from previous studies
were apparently inconsistent, the totality of the evidence to
date shows an increased risk of false positive recall in past
users of HRT without significant variation between studies
(Fig. 3). The relative risk of false positive recall diminished fol-
lowing cessation of use, but was still significantly raised in the
first few years after stopping use [3]. That the risk of false pos-
itive recall increases with increasing duration of use in past but
not current users of HRT is difficult to interpret. It is not possi-
ble to disentangle the effects of duration of use and time since
last use in the data and larger studies are required to investi-
gate whether the effect of long duration use of HRT on false
positive recall may take longer to wear off than the effect of
short duration use.
There is evidence to suggest that women who are currently
using oestrogen-only and oestrogen-progestogen HRT have a
higher proportion of their mammograms occupied by relatively
radiodense tissue, compared to women who have never used
HRT [13-15] and this remains a plausible reason for the
increase in false positive recall in users. The effects of the dif-
ferent types of HRT on false positive recall seen here, how-
ever, are not consistently explained by their observed effects
on mammographic density. Most studies find increases in
mammographic density in users of combined oestrogen-pro-
gestagen and lesser increases in users of oestrogen-only HRT
[12,16-22] (although the largest randomised trial investigating
the latter, the oestrogen-only arm of the Women's Health Initi-
ative [23], is yet to report on mammographic density), but no
significant differences are observed in this study between the
effects of oestrogen-progestagen and oestrogen-only HRT on
false positive recall [3]. Tibolone appears to have little, if any,
effect on mammographic density [24-28], consistent with the
lack of a significant effect on false positive recall seen here.
Being recalled to assessment is a stressful experience for
most women [29,30], and investigation of women who are ulti-
mately found to have a false positive screen represents a con-
siderable use of resources for screening programmes [31].
Minimisation of recall rates is, therefore, desirable. At the same
time, recall rates must be high enough to ensure adequate
cancer detection and increased recall may be justified if it
results in increased detection of breast cancer. For women
who use HRT, who are at an elevated risk of breast cancer
compared to non-users [12,32], this issue is of particular
importance. Women who use HRT are at an increased risk of
having a cancer diagnosed in the interval following a negative
screen (an interval cancer) [2,33,34], suggesting that the
increase in recall in users is not accompanied by improved
detection. The lack of any significant difference in the effect of
HRT between screening centres using single-view and two-
view mammography suggests that the more widespread adop-
tion of two-view mammography [35] may not affect the ele-
vated risk of false positive recall in women using HRT.
Conclusion
Current use of oestrogen-only and oestrogen-progestagen
HRT, but not tibolone, increases the risk of false positive recall
at screening. The elevated risk of false positive recall in users
of oestrogen-only and oestrogen-progestagen HRT was
observed consistently among the different HRT preparations
in use.
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